Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mitochondrial Pathology Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise

NCT00382473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Overweight
Interventions
Aerobic exercise program - 8 weeks
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
28 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 7, 2026, 3:37 PM EDT
Completed No phase listed Observational

Natural History Study of FDXR Mutation-related Mitochondriopathy

NCT04580979
View directory record Official record
Conditions
Neurodegenerative Disease, Hereditary, Mitochondrial Diseases, Optic Atrophy
Interventions
Mutation analysis
Genetic
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
0 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting Phase 1 Interventional

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355
View directory record Official record
Conditions
Friedreich's Ataxia (FA)
Interventions
SGT-212
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Los Angeles, California • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Regulation of Mucosal Healing in Inflammatory Bowel Disease

NCT04504136
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Serial Biopsy
Procedure
Lead sponsor
Terrence A Barrett
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Gene Therapy for the Treatment of Brain Tumors

NCT00001328
View directory record Official record
Conditions
Brain Neoplasm, Neoplasm Metastasis
Interventions
Cytovene (Ganciclovir Sodium), G1TKSVNa.53 Producer Cell Line
Drug · Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
19 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mitochondrial Remodeling After Exercise

NCT04103424
View directory record Official record
Conditions
Overweight and Obesity, Insulin Resistance, Metabolic Disease, Mitochondrial Metabolism, Sedentary Lifestyle
Interventions
Short-term Exercise Training
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 7, 2026, 3:37 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

NCT04999488
View directory record Official record
Conditions
Sarcopenia
Interventions
BPM31510, Placebo
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
65 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 7, 2026, 3:37 PM EDT
Completed No phase listed Observational

Mitochondrial Dysfunction in Phelan-McDermid Syndrome

NCT02000167
View directory record Official record
Conditions
Phelan-McDermid Syndrome
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
1 Year to 21 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

NCT03931330
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Dyspepsia, Functional Abdominal Pain Syndrome
Interventions
Percutaneous neurostimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

NCT03913143
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Sham
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
8 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
View directory record Official record
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Not listed Phase 4 Interventional

Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease

NCT02364648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MitoQ, Placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

NCT04550676
View directory record Official record
Conditions
Hiv, Fatigue, Mobility Limitation
Interventions
HIIT (intervention), CME (active control), Coaching, Control text message
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

NCT03845712
View directory record Official record
Conditions
Thymidine Kinase 2 Deficiency
Interventions
doxecitine and doxribtimine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

NCT01694940
View directory record Official record
Conditions
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
16
States / cities
San Diego, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BFR and Muscle Mitochondrial Oxidative Capacity

NCT03723226
View directory record Official record
Conditions
Mitochondria, Strength, Hypertrophy
Interventions
Low Load Resistance Exercise, Low Load Resistance Exercise + BFR
Behavioral
Lead sponsor
Louisiana State University and A&M College
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting Phase 1 Interventional

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

NCT05241262
View directory record Official record
Conditions
Mitochondrial Disease
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Michio Hirano, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Terminated Not applicable Interventional Results available

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

NCT02606279
View directory record Official record
Conditions
HIV, Aging, Sarcopenia, Angiotensin Receptor Antagonists
Interventions
valsartan, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis

NCT04678115
View directory record Official record
Conditions
Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury, Chronic Progressive External Ophthalmoplegia
Interventions
Magnetic Levator Prosthesis (MLP), Kinesiotape Frontalis Sling (KTFS)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 7, 2026, 3:37 PM EDT
Withdrawn Phase 2 Interventional

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

NCT06104358
View directory record Official record
Conditions
Diabete Type 2, Obesity
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 7, 2026, 3:37 PM EDT
No Longer Available No phase listed Expanded access

Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access

NCT01797276
View directory record Official record
Conditions
Mitochondrial Enzyme Deficiencies
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity

NCT02490527
View directory record Official record
Conditions
Statin Intolerance
Interventions
Pure epicatechin capsules (50mg), Simvastatin (40mg), Placebo
Dietary Supplement · Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 7, 2026, 3:37 PM EDT